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ORIGINAL ARTICLEPrevention and Mitigation of Experimental
Autoimmune Encephalomyelitis by Murine
b-Defensins via Induction of Regulatory
T Cells
Anika Bruhs1, Thomas Schwarz1 and Agatha Schwarz1The antimicrobial peptide murine b-defensin-14 (mBD14) was found to exert, in addition to its antimicrobial
activity, the capacity to induce regulatory T cells as demonstrated in the model of contact hypersensitivity.
Because it is induced by ultraviolet radiation, mBD14 may contribute to the antigen-specific immunosup-
pression by ultraviolet radiation. To prove whether this applies also for other immunologic models and
because ultraviolet radiation appears to have beneficial effects on multiple sclerosis, we utilized the model of
experimental autoimmune encephalomyelitis. Injection of mBD14 into mice before immunization with myelin
oligodendrocyte glycoprotein caused amelioration of the disease with less central nervous system inflamma-
tion and decreased levels of proinflammatory cytokines and cytotoxic T cells. The beneficial effect was due to
Foxp3þ regulatory T cells because it was lost on in vivo depletion of regulatory T cells. mBD14, however, also
acts in a therapeutic setting, because injection of mBD14 into mice with clinical features of experimental
autoimmune encephalomyelitis reduced the clinical score significantly. Human b-defensin-3, the human
orthologue of mBD14, induced in vitro regulatory T cell-specific markers in CD4þCD25 T cells, shifting these
nonregulatory cells into a regulatory phenotype with suppressive features. Thus, defensins may represent
candidates worth being further pursued for the therapy of multiple sclerosis.
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Multiple sclerosis (MS) is a chronic disabling autoimmune
disease affecting many people worldwide (Sahraian et al.,
2012). It is associated with the formation of inflammatory
plaques in the central nervous system (CNS) resulting in
demyelination and axonal degeneration. The incidence is
related to the geographic latitude giving rise to the speculation
that solar ultraviolet radiation (UVR) exerts beneficial effects
(Menni et al., 2012; Simpson et al., 2011). Several studies
utilizing the murine model of experimental autoimmune
encephalomyelitis (EAE) demonstrated that UVR is able to
reduce the clinical severity (Hauser et al., 1984; Leong et al.,
1996). The relevant action spectrum is in the mid (UVB,
290e320 nm) but not in the long wave (UVA, 320e400 nm)
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UVR-induced immunosuppression is caused by low phys-
iologic doses; mostly T-celledriven immune reactions are
affected (Schwarz, 2010). One of the hallmark features of
UVR-induced immunosuppression is the induction of regu-
latory T cells (Treg) (Maeda et al., 2008; Schwarz and
Schwarz, 2010). Accordingly, the beneficial effects of UVR
on EAE may be mediated via the induction of Treg as
demonstrated recently (Breuer et al., 2014).
The mechanisms by which UVR induces Treg are under
investigation. UVR impairs antigen-presenting cells in their
capacity to present antigens that subsequently do not induce
T effector cells but Treg (Schwarz et al., 2004). Most of these
studies were performed in the model of contact hypersensi-
tivity (CHS). Studies have also shown that the mechanisms by
which UVR induces Treg are several-fold.
Antimicrobial peptides (AMPs) that are produced by many
organs including the skin (Braff and Gallo, 2006) and which
play an important role in the innate defense against microbes
can be induced by UVR (Gla¨ser et al., 2009). We observed
that AMPs can suppress the adaptive immune system in
a fashion similar to UVR. Injection of the AMP murine
b-defensin-14 (mBD14) inhibited the induction of CHS and
induced Treg (Navid et al., 2012). Because of the antigen
specificity, UVR-induced immunosuppression harbors thera-
peutic potential, as in contrast to immunosuppression by
drugs, it is not associated with severe side effects. On the
other hand, any therapeutic UVR exposure is associated withestigative Dermatology. www.jidonline.org 173
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development of skin cancer. Hence, studies try to identify
alternative strategies to modulate the immune system in a
similar fashion to UVR but without causing the adverse ef-
fects of DNA damage. Based on the present findings, mBD14
might represent such a tool.
RESULTS
mBD14 ameliorates the progression of EAE
mBD14 was injected intravenously (i.v.) into mice on two
consecutive days and immunized subcutaneously with the
myelin oligodendrocyte glycoprotein (MOG)35e55 1 day after
the second injection. In the immunized group, all developed
clinical symptoms starting at around day 9 (Figure 1a), and
13% died within 3 weeks. On pretreatment with mBD14,
none died and only 87.5% developed signs of EAE. The
maximum clinical score (5.4  2.4 vs. 7.25  1.8) and the
cumulative score (26.5  11.0 vs. 36.2  15.1) were lower in
the mBD14-treated group.
Mice were killed 3 to 4 weeks after immunization; spinal
cord tissue was subjected to histopathologic analysis. In miceFigure 1. Injection of mBD14 ameliorates the progression of EAE. (a) EAE was
Data are shown as mean clinical scores of disease of eight mice per group and
versus MOG35e55 þ mBD14 by the two-tailed Mann-Whitney U-test. (b) Sectio
severity. Arrows indicate areas of cell infiltrates and lesions. scale bar upper pane
CNS were cultured for 24 hours in the presence of 2 mg/ml MOG35e55 and Fox
histogram plots are shown. Bar graph data show mean  SEM from three indep
Bonferroni corrected. CNS, central nervous system; EAE, experimental autoimmun
murine b-defensin-14.
Journal of Investigative Dermatology (2016), Volume 136with full-blown EAE, numerous inflammatory foci mainly
consisting of T cells and macrophages were found accom-
panied by neural tissue destruction. The lesions in the CNS
tissue and the inflammatory infiltrate were less pronounced
in mice pretreated with mBD14 (Figure 1b).
Mononuclear cells were isolated from the brains and
subjected to FACS analysis utilizing antibodies against CD4,
Foxp3, and glycoprotein A repetition predominant (GARP).
Foxp3 is a transcription factor expressed in CD4þCD25þ Treg
and a key regulator for the development of Treg (Hori et al.,
2003). GARP is a receptor rather specific for activated Treg
(Kalathil et al., 2013). The numbers of CD4þ/Foxp3þ and
CD4þ/GARPþ cells were significantly higher in EAE mice
pretreated with mBD14 compared with healthy control and
EAE mice (Figure 1c).
Alteration of T-cell subsets and cytokine secretion by
mBD14
To study whether peripheral T cells are also affected, lymph
node cells and splenocytes were obtained at the peak phase
of EAE and cultivated in the presence of 2 mg/ml MOG35e55.induced by immunization with MOG35e55. One group received mBD14.
are representative of three independent experiments. *P < 0.05 MOG35e55
ns of spinal cords were examined for inflammatory cell infiltrates and lesion
l ¼ 500 mm, scale bar lower panel ¼ 100 mm. (c) Mononuclear cells from the
p3, GARP and CD4 expression evaluated by FACS analysis. Representative
endent experiments. n ¼ 8 per group; *P < 0.05 EAE þ mBD14 versus EAE,
e encephalomyelitis; GARP, glycoprotein A repetitions predominant; mBD14,
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Foxp3, and GARP, respectively. The number of CD4þFoxp3þ
and CD4þGARPþ cells was significantly upregulated on
stimulation with mBD14 compared with untreated EAE ani-
mals, suggesting development of Treg (Figure 2a).
EAE is mediated by T cells that mainly secrete IFN-g and
TNF-a (Imitola et al., 2005; Mustafa et al., 1991). The
secretion of both cytokines was remarkably enhanced in
lymphocytes from EAE mice. This was reduced to control
levels when mice were treated with mBD14 (Figure 2b). IL-2
and IL-10, relevant cytokines associated with Treg induction
(Cua et al., 1999; Rouse et al., 2013), were secreted at
reduced levels by lymphocytes from EAE mice. On treatment
with mBD14 these levels were comparable with those of
control mice (Figure 2b).
mBD14 induces Foxp3D Treg in vivo and in vitro
To finally prove the induction of Treg by mBD14, we utilized
DEREG (depletion of regulatory T-cell) mice that express a
diphteria toxin (DT) receptor-enhanced green fluorescent
protein under control of the foxp3 gene (Lahl et al., 2007).Figure 2. Influence of mBD14 injection on T-cell markers and cytokine secretio
presence of MOG35e55. After 24 hours expression of Foxp3, GARP, and CD4 wa
graph data show mean  SEM from three independent experiments. n ¼ 8 per g
corresponding supernatants were analyzed for IFN-g, TNF-a, IL-2, and IL-10 usi
n ¼ 8 per group; *P < 0.05 EAE þ mBD14 versus EAE, Bonferroni corrected. EA
repetitions predominant; mBD14, murine b-defensin-14.Injection of DT results in depletion of Foxp3þ cells. DEREG
mice were immunized with MOG35e55 and treated with
mBD14 on 2 days 24 hours before immunization. One group
received DT intraperitoneally on days 6 and 7 after immu-
nization, respectively. One group was immunized only. All
mice developed clinical signs at around day 12 (Figure 3a).
Both the maximum clinical (10.6  2.6 vs. 6.0  0.7) and the
cumulative score (26.8  4.5 vs. 21.5  8.4) were higher in
mice that received DT and in mice immunized only. On DT
treatment, the expression of Foxp3 and GARP in lymphocytes
and splenocytes was downregulated (Figure 3b).
CD4þCD25 T cells were isolated and stimulated with
mBD14 in vitro. After 48 hours, 1  106 washed cells were
injected i.v. into naı¨ve mice. CD4þCD25 cells without
mBD14 pretreatment served as controls; another group
received Treg. All groups were immunized with MOG35e55
1 day after cell transfer. In the group that received mBD14-
treated CD4þCD25 cells, the maximum clinical
(3.5  0.5 vs. 6.3  0.6 and 5.5  0.5) and the cumulative
score (19.8  3.2 vs. 37.2  14.8 and 28.8  10.8) were
significantly lower as compared with the CD4þCD25 groupn in immunized mice. (a) Lymphocytes and splenocytes were cultivated in the
s evaluated by FACS analysis. Representative histogram plots are shown. Bar
roup; *P < 0.05 EAE þ mBD14 versus EAE, Bonferroni corrected. (b) The
ng ELISAs. Data shown as mean  SEM from three independent experiments;
E, experimental autoimmune encephalomyelitis; GARP, glycoprotein A
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Figure 3. Treatment with mBD14 induces Foxp3DTreg. (a) EAE was induced in DEpletion of REGulatory T cells (DEREG) mice. At day 2 and day 1, mice
were treated with 10 mg mBD14 each. DT was injected at day þ6 and day þ7 after immunization, respectively. Data are shown as mean clinical scores of
disease of eight mice per group and are representative of two independent experiments. *P< 0.05 MOG35e55 þmBD14 versus MOG35e55þmBD14 þ DT; (*)P
< 0.05 MOG35e55 þ mBD14 versus MOG35e55 by the two-tailed Mann-Whitney U-test. (b) Lymphocytes and splenocytes were cultured in the presence of
MOG35e55 for 24 hours. Expression of Foxp3 and GARP was measured by FACS analysis. Representative histogram plots are shown. Bar graph data show mean
 SEM from three independent experiments; n ¼ 8 per group; *P < 0.05 þ mBD14  DT versus EAE, **P < 0.05 þ mBD14  DT versus þ mBD14 þ DT,
Bonferroni corrected. (c) CD4þCD25 T cells were isolated and stimulated with 20 mg mBD14. 48 hours later, cells were washed and 1  106 cells were
injected i.v. into naı¨ve mice. As controls CD4þCD25 cells without mBD14 were injected; another group was injected with Treg. All groups were immunized
with MOG35e55 1 day after injection. Data are shown as mean clinical scores of disease and are representative of two independent experiments. *P < 0.05
MOG35e55 versus MOG35e55 þ CD4þCD25; (*)P < 0.05 MOG35e55 þ CD4þCD25 versus MOG35e55 þ mBD14 - CD4þCD25 by the two-tailed Mann-
Whitney U-test. (d) T cells from the brain were cultured in the presence of MOG35e55 for 24 hours. Expression of Foxp3 and GARP was measured by FACS
analysis. Representative histogram plots are shown. Bar graph data show mean  SEM from three independent experiments; n ¼ 8 per group; *P < 0.05
CD4þCD25 þ mBD14 -DT versus CD4þCD25, Bonferroni corrected. DT, diphteria toxin; EAE, experimental autoimmune encephalomyelitis; GARP,
glycoprotein A repetitions predominant; i.v., intravenous(ly); mBD14, murine b-defensin-14; Treg, regulatory T cell(s).
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mitigated EAE remarkably.
T cells were isolated from the brain of the recipient ani-
mals, restimulated with MOG35e55. FACS analysis revealed
an increase of Foxp3 and GARP in mice injected with
mBD14-stimulated CD4þCD25 cells compared with mice
that received untreated CD4þCD25 cells or which were
immunized only (Figure 3d).
mBD14 induces Foxp3 via demethylation of the foxp3
promoter
DNA methylation of 50-cytosine of CpG dinucleotides plays
an important role in gene regulation. Methylation of CpGJournal of Investigative Dermatology (2016), Volume 136islands in certain regions causes gene silencing by preventing
binding of transcription factors and by recruiting repressor
molecules. Several elements in the foxp3 gene were identi-
fied whose methylation inversely correlates with Foxp3
expression (Kim and Leonard, 2007; Lal and Bromberg,
2009; Lal et al., 2009; Morikawa et al., 2014). To analyze
changes in methylation patterns, we performed bisulfite
sequencing analysis of DNA obtained from CD4þCD25,
mBD14-treated CD4þCD25 cells, and Treg. We analyzed
the CpG sites in the promoter foxp3 CpG island region that
were identified with Methyl Primer Express v1.0 containing
38 predicted CpG sites (Figure 4a). Whereas in CD4þCD25
cells CpG sites were almost completely methylated (89%),
Figure 4. mBD14 causes
demethylation of the Foxp3 promoter
gene. TheDNAmethylation status from
DNA obtained from naive and
mBD14-treated CD4þCD25 cells as
well as Tregwas determined by bisulfite
sequencing analysis. (a) Physical map
of the murine foxp3 gene and the
location of the CpG island identified
using Methyl Primer Express v1.0
including the position of the primer
set used for amplification. (b)
Representative results from three
sequences derived from three
individual bacterial colonies are
shown. Filled (black) circles correspond
to methylated, unfilled (white) circles
correspond to unmethylated cytosines;
small vertical lines without a circle
correspond to non-CpG position where
there is a CpG in the genomic
sequence. mBD14, murine b-defensin-
14; Treg, regulatory T cell(s).
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decreased (66%). In Treg almost half of the CpG sites were
methylated (Figure 4b). This indicates that one mechanism by
which mBD14 induces Foxp3 involves changes of methyl-
ation patterns in the foxp3 promoter.
mBD14 mitigates the progression of active EAE
To test the effect of mBD14 on already developed EAE, mice
were immunized with MOG35e55 yielding clinical symptoms
on day 10. When the score reached 3, one group received
mBD14 i.v., which stopped the increase in the clinical score
(Figure 5). A total of 25% of the untreated mice died within
20 days, none in the mBD14 group. mBD14 also induced a
reduction of both the cumulative (33.0  7.8 vs. 48.3  22.1)
and the maximum clinical score (5.5  1.5 vs. 7.1  2.9).
The human AMP hBD3 switches nonregulatory T cells into a
regulatory phenotype
To elucidate whether human defensins exert similar activities,
we utilized human b-defensin-3 (hBD3), the human ortho-
logue of mBD14 (Hinrichsen et al., 2008). Human peripheral
blood mononuclear cells isolated from buffy coats of healthy
donors by Ficoll density gradient centrifugation were sepa-
rated into CD4þCD25þ and CD4þCD25 T cells by mag-
netobeads. The nonregulatory CD4þCD25 fraction was
incubated with hBD3 for 24 hours and the expression of the
Treg markers Foxp3, GARP, cytotoxic T-lymphocyte antigen
4 (CTLA-4), and neuropilin analyzed by FACS. Foxp3 and
GARP were simultaneously stained to detect double positive
cells. CD4þCD25 cells did not express Foxp3 and GARP.
Treatment with hBD3 led to an increase in double positive
cells. Treg expressed Foxp3, but GARP only minimally, which
implies that hBD3 might induce activation (Figure 6a).
CTLA-4, a negative regulator, is expressed on Treg
and essentially involved in the suppressor mechanism
(Wing et al., 2008). Incubation with hBD3 upregulated
CTLA-4 (Figure 6b). Neuropilin is expressed on activated
Treg and confers enhanced immunosuppressive activity(Chaudhary et al., 2014). Neuropilin was upregulated in
hBD3-treated CD4þCD25 cells. Together, this indicates that
hBD3 shifts CD4þCD25 T cells toward a regulatory
phenotype and causes their activation.
Whether hBD3-treated CD4þCD25 cells act suppressive
was assessed by an in vitro suppression assay. CD4þCD25
cells did not suppress proliferation of antibody-activated
CD4þCD25 T cells. In contrast, hBD3-pretreated
CD4þCD25 T cells exerted a similar suppressive activity
as CD4þCD25þ Treg (Figure 6c).DISCUSSION
Our study shows that the mBD14 reduces the clinical score
in EAE mice when injected before immunization. This clin-
ical improvement is associated with a reduction of inflam-
mation and demyelinating plaques in the CNS. The effect is
comparable with that of UVR when given before immuni-
zation. In this context it is important to notice that similar
UVR doses that improve EAE induce the release of mBD14
in vivo (Gla¨ser et al., 2009; Hauser et al., 1984; Leong et al.,
1996).
Because we injected mBD14 i.v., the question is obvious
whether exposure of the skin to UVR enhances mBD14 in the
circulation. Thus, mice were exposed to 3 kJ/m2 on three
consecutive days, blood was taken on day 4 and mBD14
levels were determined. UVR enhanced significantly the
mBD14 levels in comparison with untreated control mice
(362.1  28.8 vs. 81.5  42.4 pg/ml). These levels were even
higher than those achieved by injection of 20 mg per mouse
(122.2  4.7). We decided for the i.v. route because we knew
from previous experiments in the CHS model (Navid et al.,
2012) that intracutaneous injection of mBD14 did not result
in the induction of Treg. The successful i.v. approach implies
that mBD14 rather affects T cells than antigen-presenting
cells, which is also confirmed by our in vitro observations
(Figure 3c), showing that mBD14 shifts nonregulatory
CD4þCD25 cells into a regulatory phenotype by inducingwww.jidonline.org 177
Figure 5. mBD14 mitigates the progression of active EAE. EAE was induced
by immunization with MOG35e55. One group received 20 mg mBD14 i.v.
when the score reached 3. Data are shown as mean clinical scores of disease
of eight mice per group and are representative of three independent
experiments. *P < 0.05 MOG35e55 þ mBD14 versus MOG35e55 by the
two-tailed Mann-Whitney U-test. EAE, experimental autoimmune
encephalomyelitis; i.v., intravenous(ly); mBD14, murine b-defensin-14.
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may involve demethylation of the Foxp3 promoter.
mBD14 is also effective in reducing the clinical score
when injected after immunization into mice that suffer from
active EAE, implying that mBD14 does not only have pre-
ventive but also therapeutic potential. In contrast, to the best
of our knowledge, the latter has not yet been demonstrated
for UVR in EAE. In a pilot study, patients with MS were
exposed to total body UVR 5 days per week for 6 weeks
starting with suberythemogenic doses that were increased by
100 mJ/cm2 per session (Breuer et al., 2014). Although the
immunosuppressive effects by UVR were demonstrated by
the occurrence of Treg and of tolerogenic dendritic cells, no
changes in the neurological status were observed. The irra-
diation period may have been too short, hence further
respective studies are warranted because the fact that the MS
incidence and severity are related to the geographical lati-
tude (Simpson et al., 2011) nourishes the hypothesis that solar
radiation acts beneficial on MS.
The positive effect of mBD14 on EAE was associated with
immunological changes. The release of IFN-g and TNF-a by
lymph node cells and splenocytes was reduced and compa-
rable with healthy controls on mBD14 injection. IL-2 and IL-
10 were secreted at reduced levels by lymphocytes obtained
from EAE mice that were restored to normal levels by
mBD14. The latter two cytokines are essential for the in-
duction of Treg (Horwitz et al., 2003; Turka and Walsh,
2008). Accordingly, Foxp3 and GARP expressing Treg were
found in the CNS of mBD14-treated EAE mice. This appears
to be functionally relevant because depletion of Treg in
DEREG mice was associated with a loss of the protective
effect on EAE by mBD14.
Incubation of nonregulatory CD4þCD25 T cells with
mBD14 induces Foxp3. Even more importantly, such cells
injected i.v. mitigated the development of EAE, indicatingJournal of Investigative Dermatology (2016), Volume 136their suppressive activity. As we find in those animals more
cells expressing Foxp3 and GARP, respectively, in the CNS,
we assume that the Treg can cross the blood-brain barrier.
Because cells were washed before injection, we are quite
sure that the remnant amounts of mBD14 injected with the
cells are minimal and not responsible for any changes in the
CNS. On the other hand, we cannot exclude that when
injected i.v. mBD14 crosses the blood-brain barrier because
we have not yet performed any tracer studies.
The capacity of mBD14 to induce Treg was discovered in
the model of CHS (Navid et al., 2012). It was quite unex-
pected that a peptide that fosters the innate immune response
at the same time suppresses adaptive immunity. The rationale
for the respective investigations was the observation that the
same low UVR doses induce mBD14 on the one hand, but
suppress CHS and induce Treg on the other hand. Exposure to
UVR is associated with a disturbance of the epidermal bar-
rier. Hence induction of AMPs might make sense, thereby
preventing the invasion of microbes. On the other hand,
penetration of contact allergens is enhanced as well, and in
this case, downregulation of the immune response and in-
duction of tolerance against allergens might be regarded as
protective as well (Schwarz, 2010). By exerting this dual role
in antimicrobial activity and immunosuppression, b-defen-
sins may enable an antimicrobial defense without collateral
damage by the adaptive T-celledriven immune system.
The induction of Treg by defensins was also confirmed for
the human system. CD4þCD25 nonregulatory human T
cells expressed Foxp3, GARP, CTLA-4, and neuropilin on
incubation with hBD3. This is functionally relevant because
these cells similar to CD4þCD25þ Treg suppress T-cell
proliferation.
UVR-induced immunosuppression harbors relevant thera-
peutic potential. It is utilized for various inflammatory
dermatoses that equally well respond to immunosuppressive
drugs (Weichenthal and Schwarz, 2005). In contrast to those,
phototherapy is not associated with the long-term side effects
of immunosuppressive drugs including superinfections.
This might be due to the induction of Treg by UVR that not
only act in a preventive but also in therapeutic fashion
(Schwarz et al., 2011). Hence, it is logical to expand the
indications of diseases for phototherapy beyond dermatoses,
including MS.
The question is obvious whether the reported beneficial
effects of UVR on EAE/MS are mediated via mBD14. All we
can say at the moment is that UVR induces mBD14 in the
circulation at significant levels and that mBD14 induces,
speaking in terms of phenotype and function, similar Treg as
UVR. Hence, it is fair to speculate that mBD14 might be
involved in UVR-induced immunosuppression. On the other
hand, UVR-induced immunosuppression is multifactorial
and several pathways are involved. Hence, it may well be
that even in the absence of mBD14, UVR exerts its immu-
nosuppressive effects, maybe to a lesser extent. Irrespective of
that, the observation that mBD14 suffices to induce Treg as
UVR may be of practical importance and was the rationale of
this study. Any UVR effect appears to be associated with DNA
damage. Most of these photolesions are removed by the
nucleotide excision repair, but chronic UV exposure is
associated with cumulative DNA damage, ultimately leading
Figure 6. hBD3 switches nonregulatory human T cells into a regulatory phenotype. Human peripheral blood mononuclear cells obtained from buffy coats
were separated into CD4þCD25 and CD4þCD25þ T cells. The nonregulatory CD4þCD25 fraction was incubated with hBD3 (10 mg/ml). After 24 hours FACS
analysis was performed. (a) Foxp3 and GARP expression was evaluated by double staining. Data show mean  SEM from three independent experiments; *P <
0.05 CD4þCD25 þmBD14 versus CD4þCD25, Bonferroni corrected; representative histogram plots are shown. (b) Cells were stained either for neuropilin or
CTLA-4. Data show mean  SEM from three independent experiments; *P < 0.05 CD4þCD25 þ mBD14 versus CD4þCD25, Bonferroni corrected;
representative histogram plots are shown. (c) CD4þCD25 T cells, hBD3-treated CD4þCD25 T cells, and CD4þCD25þ T cells (Treg) were co-cultured with
CD4þCD25 responder T cells in the presence of anti-Biotin MACSiBead particles preloaded with biotinylated anti-CD2-, anti-CD3-, and anti-CD28-
antibodies. After 4 days, cell proliferation was measured using the MTT assay. Data are presented as optical density and as percent suppression calculated
according to Collison and Vignali (2011). Data shown as mean  SEM from three independent experiments; *P < 0.05 hBD3-treated CD4þCD25 cells versus
CD4þCD25 cells; P > 0.05 hBD3-treated CD4þCD25 cells versus Treg. CTLA-4, cytotoxic T-lymphocyte antigen 4; hBD3, human b-defensin-3; GARP,
glycoprotein A repetitions predominant; Treg, regulatory T cell(s).
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similar immunosuppressive effects but without the need of
UVR. b-Defensins and related peptides might represent such
an alternative that of course has to be proven in future
studies.
MATERIALS AND METHODS
Mice
Seven- to eight-week-old female C57BL/6J mice were purchased
from Charles River Laboratories (Sulzfeld, Germany). Depletion
of regulatory T-cell mice were provided by T. Sparwasser (Lahl
et al., 2007). To deplete Foxp3-positive cells, mice were injec-
ted intraperitoneally with 500 ng DT (Merck, Darmstadt, Ger-
many). Mice were bred in the central animal facilities of theUniversity Clinics. Animal care was utilized by expert personnel
under specific pathogen-free conditions in compliance with
relevant laws and institutional guidelines. Experiments were
approved by the institutional review board.
Induction of EAE
EAE was induced by subcutaneous injection of 100 ml of a 1:1
emulsion of 20 mg MOG35e55 and 200 mg Mycobacterium tuber-
culosis in complete Freund’s adjuvant. Pertussis toxin (300 ng) was
injected intraperitoneally on the day of immunization (defined as
day 0); a second dose was administered 48 hours later (day þ2).
Clinical disease was assessed using the following criteria: 0, no
disease; 1, distal limp tail; 2, limp tail; 3, righting reflex impaired; 4,
no righting reflex; 5, unsteady gait; 6, hind limb paresis; 7, hind limbwww.jidonline.org 179
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180paralysis; 8, hind limb paralysis with hind body paresis; 9, weakness
in forelimbs; 10, quadriplegia; 11, moribund or death.
Preparation of tissues and histologic staining
Mice were euthanized and spinal cords were dissected and
embedded in paraffin. Sections were stained with hematoxylin and
eosin and examined under a microscope (Zeiss, Axioscope 40,
Oberkochen, Germany).
Isolation of murine cells
To isolate mononuclear cells from the CNS, brain tissue was minced
and digested in a 1625 units/ml collagenase IV solution for 15 mi-
nutes at 37 C. Single cell suspension was prepared by passing
through a 70-mm cell strainer. After washing with Hank’s Balanced
Salt Solution supplemented with 1 mM EDTA and 2% fetal calf
serum, cells were resuspended in 3 ml 40% Percoll and placed on 4
ml of a 70% Percoll cushion. After centrifugation for 30 minutes at
425  g, the interphase was washed and analyzed by FACS.
Single cell suspensions were obtained by passing lymph nodes
and spleens through a 100-mm cell strainer. After erythrocyte lysis,
cells were maintained in complete RPMI 1640 media supplemented
with 10% fetal calf serum, 1% nonessential amino acids, 1%
L-glutamine, 1% sodium pyruvate, 10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), and 50 mM 2-Mercaptoe-
thanol (2-ME) at a concentration of 1  106 cells/ml in six-well
plates. Cells were stimulated with 2 mg/ml MOG35e55. After 24
hours, supernatants were collected for cytokine determination by
ELISAs (BioLegend, San Diego, CA) and cells were subjected to FACS
analysis.
CD4þCD25 and CD4þCD25þ T cells were isolated via a
magnet-activated cell sorter (MACS; CD4þCD25þ Regulatory T Cell
Isolation Kit; Miltenyi Biotec, Bergisch-Gladbach, Germany). Cells
were maintained in complete RPMI 1640 supplemented with 10%
fetal calf serum, 1% nonessential amino acids, 1% L-glutamine, 1%
sodium pyruvate, 10 mM HEPES, and 50 mM 2-ME at a concentra-
tion of 1  106 cells/ml. Cell viability of each separation was tested
by trypan blue dye exclusion and was always greater than 90%. The
viability was not affected by the cultivation for 24 hours.
Isolation of human lymphocytes
Human peripheral blood mononuclear cells were isolated from
buffy coats by Ficoll density gradient centrifugation (Lymphoprep,
STEMCELL Technologies, Ko¨ln, Germany). Cells were separated into
CD4þCD25þ and CD4þCD25 T cells by magnetobeads.
CD4þCD25 cells were incubated with 10 mg/ml hBD3 (kindly
provided by J. Harder, Kiel) for 24 hours.
Flow cytometric analysis
Allophycocyanin-conjugated anti-mouse CD4, phycoerythrin-
conjugated anti-mouse Foxp3, and anti-mouse GARP antibody
were used for FACS (FC500; Beckman Coulter, Krefeld, Germany).
Cells were gated on size and granularity and 10,000 cells analyzed
for the relevant fluorochromes. Percentages of positive cells from the
samples were compared with the IgG control that was set as 1.
Proliferation assay
A total of 5  105 cells/ml CD4þCD25 responder T cells were
seeded into 96 well plates and mixed with CD4þCD25þ cells,
CD4þCD25 cells, and hBD3-treated CD4þCD25 cells, respec-
tively, at the ratios 2:1 and 4:1. Anti-Biotin MACSiBead particles
preloaded with biotinylated anti-CD2-, anti-CD3-, and anti-CD28-
antibodies were added for T-cell stimulation. After 4 days, cellJournal of Investigative Dermatology (2016), Volume 136proliferation was measured by MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazoliumbromid) tetrazolium reduction assay.
Methylation analysis
Genomic DNA was isolated using the DNeasy Blood & Tissue Kit
(Qiagen, Hilden, Germany). Sodium bisulfite treatment of genomic
DNA was performed using the peqGOLD Bisulfite Conversion Kit
(peqlab, Erlangen, Germany). The promoter foxp3 CpG island region
from 4732 to 3991 containing 38 CpG sites that were identified
with Methyl Primer Express v1.0 was amplified using the following
primers:ter primer forward, 50-GGTAACGAAAATGTGGGTATTAGG-30
ter primer reverse, 50-CGCCTTTTCAAACCCTACCC-30
er primer forward, 50-GTTAGAGGTAGTTTTAGGGTTT-30
er primer reverse, 50-CGCCTTTTCAAACCCTACCC-30PCR products were separated on agarose gels, purified, and
cloned into the pGEM-T easy vector (Promega, Madison, WI). Re-
combinant plasmid DNA from the individual bacterial colonies were
purified and sequenced.
Statistical analysis
For FACS and ELISA, data statistical analysis was performed using
Student’s t-test. For multiple comparisons we carried out one-way
ANOVA to assess whether at least two groups significantly differ.
For pairwise post hoc analysis, we applied Bonferroni correction. For
EAE experiments, the Mann-Whitney U-test was used for deter-
mining the level of significance of differences between sample
means. Values of P < 0.05 were considered statistically significant.
Unless otherwise stated, data show one representative of three
independently performed experiments with at least eight mice per
group.
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